Abhishek Sinha
The Rubicon Research IPO comprised a fresh issue of ₹500 crore and an offer-for-sale (OFS) worth ₹877.5 crore by promoter General Atlantic Singapore RR Pte Ltd.
Of the fresh issue proceeds, ₹310 crore will be used for debt repayment, while the remaining funds will go toward strategic acquisitions, expansion initiatives, and general corporate purposes.
The price band was fixed at ₹461–₹485 per share, with a lot size of 30 shares and multiples thereof. The IPO allocation structure followed the standard pattern — QIBs (75%), NIIs (15%), and Retail Investors (10%).
The issue was managed by a consortium of lead book-running managers, including JM Financial, Axis Capital, IIFL Capital, SBI Capital Markets, and MUFG Intime India Pvt. Ltd.
What’s Next
Rubicon’s listing will be closely watched as it follows a series of successful pharma IPOs in 2025. Analysts believe the company’s robust R&D capabilities and focus on complex generics could drive sustained market interest post-listing.
However, experts advise investors to watch post-listing price stability, as initial euphoria in oversubscribed IPOs often gives way to profit booking.
Key Highlights:
| Particulars | Details |
|---|---|
| Listing Date | October 16, 2025 |
| IPO Price Band | ₹461 – ₹485 per share |
| Estimated Listing Price (as per GMP) | ₹628 |
| Grey Market Premium (GMP) | ₹143 |
| Subscription | 103.90x overall |
| QIBs / NIIs / Retail | 130.26x / 97.61x / 35.47x |
| Funds Utilization | Debt repayment, acquisitions, and expansion |
